Activity of ceftaroline and comparators against pathogens isolated from skin and soft tissue infections in Latin America - results of AWARE surveillance 2012.
As part of the Assessing Worldwide Antimicrobial Resistance Evaluation (AWARE) surveillance program in 2012 the in vitro activity of ceftaroline and relevant comparator antimicrobials was evaluated in six Latin American countries (Argentina, Brazil, Chile, Colombia, Mexico and Venezuela) against pathogens isolated from patients with hospital associated skin and soft tissue infections (SSTIs). The study documented that ceftaroline was highly active (MIC90 0.25mg/L/% susceptible 100%) against methicillin-susceptible Staphylococcus aureus, methicillin-resistant S. aureus (MIC90 2mg/L/% susceptible 83.3%) and β-hemolytic streptococci (MIC90 0.008-0.015mg/L/% susceptible 100%). The activity of ceftaroline against selected species of Enterobacteriaceae was dependent upon the presence or absence of extended-spectrum β-lactamases (ESBLs). Against ESBL screen-negative Escherichia coli, Klebsiella pneumoniae, and Klebsiella oxytoca the MIC90 and percent susceptible for ceftaroline were (0.5mg/L/94.1%), (0.5mg/L/99.0%) and (0.5mg/L/91.5%), respectively. Ceftaroline demonstrated potent activity against a recent collection of pathogens associated with SSTI in six Latin American countries in 2012.
International Health Management Associates Inc., Schaumburg, USA.
Daryl
D
Hoban
International Health Management Associates Inc., Schaumburg, USA. Electronic address: dbiedenbach@ihmainc.com.
Douglas
D
Biedenbach
International Health Management Associates Inc., Schaumburg, USA.
Daniel
D
Sahm
AstraZeneca Pharmaceuticals, Waltham, USA.
Edina
E
Reiszner
AstraZeneca Pharmaceuticals, Waltham, USA.
Joseph
J
Iaconis
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D002511:Cephalosporins / Q000494:pharmacology*; D062665:Epidemiological Monitoring; D006090:Gram-Negative Bacteria / Q000145:classification / Q000187:drug effects*; D006094:Gram-Positive Bacteria / Q000145:classification / Q000187:drug effects*; D006801:Humans; D007843:Latin America; D008826:Microbial Sensitivity Tests; D017192:Skin Diseases, Bacterial / Q000382:microbiology; D018461:Soft Tissue Infections / Q000382:microbiology; D000097583:Ceftaroline
D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D000097583:Ceftaroline
Ceftaroline; Latin America; Skin pathogens